Member Info for jint

Manifesto....I had the same...refreshed a few times and it came back....but you won’t get this message until your hooked up again.....irritating to say the least....

GLA

Bosi:

Your find at the very least....confirms that SGN001 is circulating the halls of Westminster....

GLA

Bosi:
Just copied and pasted your great find....
As some on board couldn’t open it....
Hope you don’t mind....

GLA

COVID 19 James Kennan v5
6

Governments Response to the COVID-19 Project James A Kennan
The above would give a status of the programme at the moment.
What is also needed is a Treatment Plan for COVID 19 for Approved Treatments and Novel Treatments. Patients with COVID 19 can relapse with mild COVID 19 to Critical COV- 19. Part of the treatment plan is to treat the patients in a timely so they do not relapse. In the case of SNG it has been prescribed to patients with severe or critical COVID -19. However what is required is to determine if a patient with mild COVID 19 will relapse and need treatment.
In addition a What if exercise should be undertaken.
The Oxford Vaccine has nearly completed its safety and is starting its effectiveness trial. It is largely de risked. Given the knowledge about the immune systems now and the experience what is the technical analysis of any problems that there are in achieving effectiveness. Can the effectiveness be demonstrated by analysis or does it have to be a trial. If a trial is necessary could a small trial be initiated to prove this. See Annexe C Vaccines.
If SNG 001 could be fast tracked could the trial where vaccinated volunteers were infected with COVID 19. If the vaccine did not protect them they could be treated with an approved SNG 001.
Could Tocilizumab be fast tracked as well as other treatments. Observational trials could be used with some Emergency Authorisation. This may provide useful backup.
What other work around can be used?
Implementation Phase
The implementation phase depends on the review from the of Developing of Treatment for COVID - 19.
There is no specified effective rate for drugs. It depends on a lot of factors it is not a tick box exercise. It depends on the prognosis of the patient if they are not treated, if the treatment will be more effective in administration, the competition drug and cost among others If the prognosis is death and there are no competition drugs a drug with a effectiveness of 50% be approved.
However SNG 001 can be approved first and has an effective rate of 79% this would be considered an excellent result and would be approved. Not many drugs have a effectiveness ratio of greater than 80%. In report [ ] the mortality rate is 24.6% of the number of patients admitted to hospital with COVID -19. This is an extremely high mortality rate. SNG 001 is approved the mortality rate would reduce this to 5.1%.
If SNG001 is approved before Oxford Vaccine it would be possible to use SNG001 as the treatment. If Oxford Vaccine was proved safe it could then be issued at risk as SNG was close to authorisation saving a lot of time distributing the vaccine when approved.
Only the Oxford Vaccine may be approved which would entail a longer lock down period and different policies.
It will take a long time to distribute the treatments after approval but pre planning could help.
Advantages of Planning
If basic form of planning that shows the beginning and end dates an

There would also be a Outline Plan for the Equipment.
? PPE
? Ventilators
? Test Equipment
The outline plan milestones would be monitored on a weekly basis. It would have the appropriate milestones for drugs listed below such as design, manufacture and test where appropriate approval. If this monitoring showed no drugs could be approved the Project Team would know this at an early stage and could take appropriate action.
Development of Treatment for COVID 19
At a suitable stage in the project when some treatments have made significant progress the total project should be reviewed with a view to bringing it to completion.
The UK is in a fortunate position there are two candidates, one Imperial College and the other Oxford University. The Oxford University vaccine is more advanced so will be considered at this phase.
At this stage no Plasma Results announced
The following will be projects will be selected
Vaccine : Oxford University
Approved Treatments: Dexamethasone There appear to be some anomalies in the results that are
being checked. The results from all patients on Dexamethasone trial indicated a mortality rate of 21.6 %for usual care and 24.6% for those on Dexamethasone for those not on Oxygen and Mechanical Intervention.
This did not indicate a significant difference so not considered a candidate at this stage.. See Annexe B Dexamethasone Recovery Report
Novel Treatments: Synairgen has announced positive results from trial of SNG001. The odds of developing severe disease (e.g. requiring ventilation or resulting in death) during the treatment period (day 1 to day 16) were significantly reduced by 79% for patients
It is not true to say that the only way to prevent the spread of COVID 19 is a vaccine. It is only true if there are no proven Approved Treatments, Novel Treatment or Plasma. The present palliative treatment is very expensive because of the number of days the patients are in hospital, the equipment needed and the medical care. Synairgen SNG001, can be used to treat patients at home or a centre for this purpose. This would be considerably cheaper than hospital resources and free up resources for patients that do not have COVID 19.
What should be investigated are Oxford Vaccine
? The number of volunteers in the UK for the Oxford Vaccine
? Time frame to demonstrate the Vaccine is Safe
? Time frame to Approve the Vaccine
Approved Treatments
? Decision on whether to approve Dexamethasone or not
? The resources to approve Dexamethasone
? Whether to fast track other Drugs
? Whether to cancel Recovery and invest in pipeline antiviral
Novel Drugs
? The resources in terms of patients to ensure SNG001 is safe
? The resources in terms of patients to approve SNG001
? The Timescales
File COVI

CityTTrader:

Totally agree with your sentiments re: valuation....

if given the go ahead this therapeutic could have profound effects on confidence economically.....

I believe this has the potential to be a game changer and thereby give the Footsie a welcome boost....and also hopefully my investments there....

Clairesmith:
Thank you for your post.....

This article really underlines the need for SGN001 to be made available to non hospitalised Covid sufferers under medical supervision.....once approval is granted....

GLA

Vorag:

Agreed.....good to make issues crystal clear on the board...

GLA

SGD27:

Filing date versus Submission date just terminology means the same....filing at the Patent Office

Vorag:

I agree it isn’t kosher from the minute you submit......but Synairgen have the patent on SGN001 therefore no one can obtain a patent regarding SGN001 in conjunction with steroid use......
I therefore remain fully confident with their submitted patent application....

GLA

To add to that statement.....to lengthen the patents life also.....

GLA

I have absolutely no concerns that this new patent application will be granted....
The use of steroids in conjunction with SGN001 was NOT obvious and was therefore novel.....it hadn’t been tried before....
The Synaigen team wouldn’t have just suddenly thought about this and applied for a patent......
They would already had for months now a list of possibilities regarding SGN001 being used in conjunction with various other medications......
The possibilities don’t end with this application either.....
the trick is to broaden the patent as far as possible to protect intellectual property rights......
They definitely know what they are doing and I trust their judgment......

GLA

and hewhodares1....

HelloSanDiego:
Trials have to have end dates inserted...as these are Pivotal Trials if success can be achieved before end the dates emergency approval can be sanctioned...

Estimated Primary completion date
The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "estimated" primary completion date is the date that the researchers think will be the primary completion date for the study.

Estimated Study completion date
The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "estimated" study completion date is the date that the researchers think will be the study completion date.

Hope this helps....

Parsley2.....you stand out like a sore thumb....go get it look at!!!

Neither.... just useful info....SNG001 mentioned in interferon section.....

Not sure if already posted so apologies in advance.....

https://www.google.co.uk/amp/s/www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.amp.html

GLA

Chrishar:
You are absolutely correct in your assumptions......although frustrating at times for all.....patience and yet more patience is the key to maximise potential profits....

and likewise to get this fantastic product to market to help alleviate the suffering of many millions around the world....

GLA

Much higher on the possibility’s ahead...£8 - £10....wouldn’t be surprise if it went even further.....imo

Morning: Crazy figures to ponder on over the weekend.....

1 billion divided by 149,430,000 Shares = £6.692

1 billion = £6.69 per share
2 billion = £13.38 ditto
3 billion = £20.07 ditto
4 billion = £26.76 ditto
5 billion = £33.45 ditto

These are astonishing numbers but quite possible......

GLA...